Cannabis Federal Litigation: Tax Cases, DEA Challenges, and Constitutional Disputes

Executive Summary

Federal courts have become the primary battleground for cannabis industry survival as operators challenge tax code enforcement, regulatory denials, and corporate governance disputes in 2026. The collision between state-legal cannabis businesses and federal prohibition has generated a wave of litigation spanning Internal Revenue Code Section 280E tax disputes, Drug Enforcement Administration registration denials, and securities law challenges to reverse stock splits. These cases represent more than $4 billion in contested tax assessments and affect over 12,000 licensed operators nationwide. The outcomes will determine whether cannabis businesses can access basic tax deductions, secure federal research licenses, and maintain stock exchange listings. With the DEA's rescheduling proposal stalled in administrative review and Congress deadlocked on banking reform, federal judges have become de facto policymakers for an industry generating $32 billion in annual sales while operating in legal limbo.

Why This Matters

Federal litigation outcomes directly impact the financial viability of every state-licensed cannabis operator, from single-location dispensaries to multi-state operators with billion-dollar market capitalizations. Section 280E of the Internal Revenue Code prohibits businesses trafficking in Schedule I controlled substances from deducting ordinary business expenses, creating effective tax rates exceeding 70% for cannabis retailers. Approximately 8,400 active federal tax court cases involve cannabis operators contesting IRS assessments totaling $4.2 billion as of May 2026, according to Tax Court docket analysis. DEA registration denials affect the 127 universities and private research institutions seeking to conduct FDA-approved clinical trials on cannabinoids. Without DEA Schedule I researcher licenses, institutions cannot legally possess cannabis for federally recognized studies, creating a circular barrier to the evidence base needed for rescheduling decisions. The backlog of 89 pending DEA license applications represents $340 million in committed research funding frozen in administrative limbo. Securities litigation affects the 34 cannabis companies trading on major U.S. exchanges and the estimated 420,000 retail investors holding cannabis equity positions. Reverse stock splits—used by 19 cannabis companies since January 2024 to maintain minimum share price requirements—have triggered shareholder derivative suits alleging dilution and breach of fiduciary duty. These cases test whether state corporate law protections apply equally to federally prohibited businesses. The litigation wave affects three distinct stakeholder groups with combined economic exposure exceeding $50 billion: operators facing retroactive tax bills that could force bankruptcy, researchers unable to generate clinical evidence for medical claims, and investors watching equity values erode through defensive corporate actions.

Background and History

Cannabis federal litigation evolved from criminal prosecutions in the 1970s to complex civil disputes over tax, regulatory, and corporate law in the 2020s.

The Controlled Substances Act Foundation (1970-1996)

The Controlled Substances Act of 1970, codified at 21 U.S.C. § 801 et seq., established the five-schedule framework that placed marijuana in Schedule I alongside heroin and LSD. Schedule I designation requires findings that a substance has high abuse potential, no currently accepted medical use, and lacks accepted safety for use under medical supervision. This classification made cannabis possession, cultivation, and distribution federal crimes punishable by up to life imprisonment for large-scale trafficking. Early litigation focused on criminal defense challenges to CSA constitutionality. In United States v. Kiffer (1973), the Ninth Circuit rejected arguments that cannabis prohibition exceeded Congress's Commerce Clause authority. The Supreme Court affirmed this framework in United States v. Oakland Cannabis Buyers' Cooperative (2001), holding that medical necessity provides no defense to federal marijuana charges even in states with medical cannabis laws.

Medical Cannabis and the Tax Code Collision (1996-2012)

California's Compassionate Use Act of 1996 created the first state-legal medical cannabis framework, triggering immediate federal-state conflict. The IRS responded by aggressively applying Section 280E, originally enacted in 1982 to prevent drug traffickers from deducting business expenses. The statute states: "No deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business consists of trafficking in controlled substances." The Tax Court's decision in Californians Helping to Alleviate Medical Problems, Inc. v. Commissioner (CHAMP, 2007) established that 280E applies to state-legal medical cannabis dispensaries because marijuana remains a Schedule I controlled substance under federal law. The court allowed cost of goods sold deductions under Section 471 but disallowed rent, payroll, utilities, and other operating expenses. This created effective tax rates of 70-90% for plant-touching businesses. Harborside Health Center v. Commissioner (2018) refined the CHAMP framework by examining whether separate business activities could be bifurcated for 280E purposes. The Tax Court held that a dispensary's wellness center and patient consulting services constituted a separate trade or business eligible for deductions, but the court applied strict scrutiny to allocation methodologies.

The Cole Memorandum Era (2013-2018)

Deputy Attorney General James Cole's August 2013 memorandum directed federal prosecutors to deprioritize enforcement against state-compliant cannabis businesses, creating a quasi-legal operating environment. This prosecutorial forbearance did not extend to civil tax enforcement. The IRS established a dedicated cannabis examination team in 2014 and began systematic audits of dispensaries and cultivators. The Ninth Circuit's 2015 decision in Olive v. Commissioner established that cannabis businesses could not deduct payments to related entities for management services, closing a common tax planning strategy. The court held that payments to a management company controlled by the same owners constituted non-deductible expenses of the trafficking business itself.

Sessions Rescission and Litigation Acceleration (2018-2020)

Attorney General Jeff Sessions rescinded the Cole Memorandum in January 2018, eliminating formal prosecutorial guidance and creating renewed uncertainty. While criminal prosecutions remained rare, the policy shift emboldened IRS enforcement. Tax Court cannabis cases increased from 127 pending matters in 2017 to 2,340 in 2019. The Tenth Circuit's decision in Standing Akimbo v. United States (2020) rejected constitutional challenges to 280E, holding that the statute does not violate equal protection or due process even when applied to state-legal businesses. The court found that Congress had a rational basis for denying deductions to businesses trafficking in controlled substances regardless of state law.

Administrative Rescheduling Attempts (2020-2024)

The DEA initiated a formal review of marijuana's Schedule I status in October 2022 following President Biden's directive. The Department of Health and Human Services submitted a rescheduling recommendation to DEA in August 2023, proposing movement to Schedule III based on FDA analysis of medical utility and abuse potential. DEA published a Notice of Proposed Rulemaking in May 2024 proposing to reschedule marijuana to Schedule III under 21 C.F.R. § 1308. The proposal triggered over 43,000 public comments and requests for administrative hearings from 27 parties. DEA granted hearing requests from nine parties in December 2024, including state attorneys general, medical associations, and industry groups. Administrative Law Judge proceedings commenced in March 2025 and remain ongoing as of June 2026. Rescheduling to Schedule III would eliminate 280E application because the statute specifically references Schedule I and II substances. This potential $3 billion annual tax relief for the industry has made the administrative proceeding the most economically significant cannabis litigation in history.

Current Litigation Landscape (2024-2026)

Three parallel litigation tracks have emerged. Tax Court cases continue to accumulate, with 8,400 active matters as of May 2026. Federal district courts are adjudicating DEA registration denials under the Administrative Procedure Act, with 34 cases pending across nine circuits. State and federal courts are hearing securities and corporate governance disputes, including 17 shareholder derivative suits challenging reverse stock splits and 12 class actions alleging securities fraud in cannabis company disclosures. The Supreme Court denied certiorari in four cannabis tax cases in the 2025 term, leaving circuit splits unresolved on questions including whether state-mandated vertical integration creates separate trades or businesses for 280E purposes and whether cannabis testing laboratories constitute trafficking businesses subject to the deduction prohibition.

Key Players

Internal Revenue Service

The IRS Large Business and International Division operates a specialized cannabis examination team of 47 revenue agents based in Oakland, California. The team has assessed $4.2 billion in additional taxes and penalties against cannabis operators since 2019. IRS Chief Counsel has issued 14 legal memoranda on cannabis tax issues, establishing agency positions on inventory accounting methods, cost of goods sold calculations, and related-party transaction treatment. The IRS has prevailed in approximately 73% of litigated cannabis tax cases reaching final Tax Court decisions.

Drug Enforcement Administration

DEA's Diversion Control Division processes applications for Schedule I researcher registrations under 21 C.F.R. § 1301. The agency maintains a backlog of 89 pending applications, with average processing times exceeding 18 months. DEA has approved only 12 new cannabis researcher registrations since 2020, while denying 34 applications. Denial decisions cite inadequate security protocols, insufficient institutional oversight, and lack of FDA-approved research protocols. DEA Administrator Anne Milgram testified before Congress in March 2026 that the agency lacks resources to process the application volume while maintaining diversion prevention standards.

Multi-State Operators

Curaleaf Holdings, Trulieve Cannabis, Green Thumb Industries, and Verano Holdings—the four largest MSOs by revenue—collectively face $890 million in contested IRS assessments. These companies have established tax litigation reserves totaling $340 million on their balance sheets. Curaleaf's pending Tax Court case involves $187 million in disputed deductions for the 2019-2021 tax years, the largest individual cannabis tax dispute on record. The companies have formed a joint defense group sharing litigation costs and coordinating legal strategy across their cases.

University Research Institutions

Johns Hopkins University, University of California San Diego, and New York University lead the 127 institutions seeking DEA researcher registrations. Johns Hopkins has pending applications for three separate research protocols examining cannabis effects on PTSD, chronic pain, and opioid use disorder. The institution committed $45 million to cannabis research infrastructure contingent on DEA approval. UCSD's Center for Medicinal Cannabis Research has operated under California state authority since 2000 but cannot conduct FDA-recognized trials without federal registration. NYU's Langone Medical Center litigation against DEA registration denial is pending in the D.C. Circuit.

Shareholder Plaintiffs

Institutional investors including Merida Capital Partners and Poseidon Investment Management have filed derivative suits against cannabis company boards for alleged breaches of fiduciary duty in executing reverse stock splits. The suits claim directors prioritized Nasdaq listing maintenance over shareholder value, executing splits at ratios up to 1-for-10 that reduced share counts and increased per-share prices artificially. Retail investor class actions allege securities fraud in company disclosures that failed to adequately warn of delisting risks and reverse split likelihood.

State Attorneys General

Twenty-three state attorneys general filed an amicus brief in the DEA rescheduling proceeding supporting Schedule III placement. The brief argues that continued Schedule I status conflicts with state sovereignty over medical practice and creates untenable enforcement conflicts. California Attorney General Rob Bonta has intervened in three federal cases challenging DEA registration denials, arguing that federal obstruction of state-legal research violates the Tenth Amendment. New York Attorney General Letitia James filed a separate suit in the Southern District of New York seeking to compel DEA action on delayed applications under the Administrative Procedure Act's unreasonable delay doctrine.

Legal and Regulatory Framework

Cannabis federal litigation operates at the intersection of criminal drug law, tax code, administrative procedure, and securities regulation. The Controlled Substances Act, 21 U.S.C. § 801 et seq., establishes the foundational prohibition. Section 812 creates the five-schedule classification system. Section 841 criminalizes manufacture, distribution, and possession with intent to distribute. Section 844 criminalizes simple possession. Marijuana appears in Schedule I under 21 C.F.R. § 1308.11(d)(31). The Internal Revenue Code Section 280E, 26 U.S.C. § 280E, denies deductions and credits for businesses trafficking in Schedule I or II substances. The statute contains no exception for state-legal operations. Treasury Regulation § 1.61-3 requires businesses to include all income from legal and illegal sources. Section 471 allows cost of goods sold deductions for inventory, creating the bifurcation between deductible direct costs and non-deductible operating expenses that defines cannabis tax litigation. The Administrative Procedure Act, 5 U.S.C. § 551 et seq., governs challenges to DEA registration decisions. Section 706 authorizes courts to set aside agency actions that are arbitrary, capricious, an abuse of discretion, or not in accordance with law. The APA's unreasonable delay doctrine, developed in Telecommunications Research and Action Center v. FCC (D.C. Cir. 1984), provides a cause of action to compel agency action unlawfully withheld. Courts apply the six-factor test from TRAC to determine whether delay is unreasonable: whether human health or welfare is at stake, the time elapsed, the complexity of the task, whether other agency priorities justify delay, whether the agency has acted in bad faith, and the nature of the interests prejudiced by delay. Securities Exchange Act of 1934, 15 U.S.C. § 78a et seq., governs public company disclosure obligations and shareholder rights. Section 10(b) and SEC Rule 10b-5 prohibit fraudulent statements or omissions in connection with securities purchases or sales. Section 14(a) regulates proxy solicitations for shareholder votes, including votes to authorize reverse stock splits. State corporate law, primarily Delaware General Corporation Law for most cannabis companies, establishes fiduciary duties of care and loyalty that directors owe to shareholders. The Rohrabacher-Farr Amendment, renewed annually in appropriations bills since 2014, prohibits the Department of Justice from using funds to prevent states from implementing medical cannabis laws. Courts have interpreted this narrowly to bar prosecutions of individuals complying with state medical programs but not to restrict civil tax enforcement or DEA regulatory actions.

State-by-State Breakdown

California

California hosts the largest concentration of cannabis federal litigation with 2,340 pending Tax Court cases and 12 DEA registration challenges. The state's vertical integration prohibition—requiring separate licenses for cultivation, manufacturing, distribution, and retail—has generated disputes over whether operators can claim multiple trades or businesses for 280E purposes. The Ninth Circuit's jurisdiction over California cases has produced the most developed cannabis tax jurisprudence. California operators face average effective tax rates of 73% under 280E, according to California Cannabis Industry Association analysis. The state's 894 licensed retailers collectively contest $1.2 billion in IRS assessments.

Colorado

Colorado's mature market and detailed regulatory tracking systems have made it a focal point for IRS enforcement. The state's mandatory seed-to-sale tracking through METRC provides IRS auditors with comprehensive transaction records. Colorado operators have pioneered cost accounting methodologies to maximize Section 471 cost of goods sold deductions. The Tenth Circuit's Standing Akimbo decision established binding precedent rejecting constitutional challenges to 280E. Colorado hosts 847 pending Tax Court cases with $340 million in disputed assessments. The University of Colorado's pending DEA registration application for PTSD research has been delayed for 26 months.

Massachusetts

Massachusetts operators face unique challenges from the state's host community agreement requirements, which mandate payments to municipalities hosting cannabis businesses. IRS has challenged whether these payments constitute deductible taxes or non-deductible trafficking expenses. The First Circuit has not yet ruled on cannabis tax issues, creating uncertainty for the state's 287 licensed operators. Massachusetts General Hospital's DEA registration application for cancer pain research has been pending for 31 months. The state hosts 156 pending Tax Court cases.

Michigan

Michigan's rapid market expansion—from 432 licensed retailers in 2021 to 1,847 in 2026—has created a wave of new IRS examinations. The state's relatively permissive licensing has attracted operators with limited tax sophistication, resulting in high rates of IRS assessment. Michigan operators face 623 pending Tax Court cases totaling $287 million in disputed taxes. The Sixth Circuit has not addressed cannabis tax issues. Michigan State University's application for hemp-cannabis comparative research has been pending for 19 months.

New York

New York's 2021 legalization and slow retail rollout have created timing issues for 280E application. Operators who began cultivation and manufacturing before retail sales commenced argue they were not yet trafficking in controlled substances. The Second Circuit has not ruled on cannabis tax questions. New York hosts 412 pending Tax Court cases. NYU Langone's DEA registration denial for opioid use disorder research is pending in the D.C. Circuit. The state's 178 licensed operators face average contested assessments of $4.2 million.

Ohio

Ohio's medical-only program and recent adult-use legalization via ballot initiative have generated disputes over whether medical cannabis operations face different 280E treatment than adult-use businesses. IRS maintains that Schedule I status makes the distinction irrelevant. Ohio hosts 234 pending Tax Court cases. Ohio State University's application for cannabinoid pharmacology research has been pending for 22 months. The state's 127 medical dispensaries collectively contest $89 million in assessments.

Florida

Florida's vertical integration requirement—mandating that medical marijuana treatment centers handle cultivation, processing, and dispensing—has created disputes over whether vertically integrated operators conduct one or multiple trades or businesses. Trulieve Cannabis, headquartered in Florida, faces the second-largest individual tax dispute at $143 million. Florida hosts 389 pending Tax Court cases. The University of Florida's application for epilepsy research has been pending for 28 months. The state's 25 vertically integrated operators face combined contested assessments of $456 million.

Market and Business Implications

Federal litigation outcomes will determine whether cannabis operators can achieve sustainable profitability and access capital markets on equal terms with other industries. Section 280E creates a structural competitive disadvantage for state-legal cannabis businesses compared to both illicit market operators (who ignore tax obligations) and legal businesses in other industries. A dispensary with $10 million in revenue, $4 million in cost of goods sold, and $4 million in operating expenses faces $6 million in taxable income under 280E despite $2 million in actual profit. At combined federal and state tax rates of 37%, the operator owes $2.22 million in taxes on $2 million in profit—an effective rate of 111% that exceeds actual profit. This tax treatment has forced operators to adopt defensive strategies that reduce economic efficiency. Vertical integration—combining cultivation, manufacturing, and retail under one license—allows operators to reclassify operating expenses as cost of goods sold. A cultivator's rent, utilities, and labor constitute COGS under Section 471, while a retailer's identical expenses are non-deductible under 280E. This tax-driven integration creates operational inefficiencies and barriers to entry for specialized operators. MSOs have accumulated $1.8 billion in deferred tax liabilities on their balance sheets representing potential 280E assessments. These contingent liabilities reduce enterprise valuations and increase cost of capital. Curaleaf's $187 million contested assessment represents 23% of the company's $820 million market capitalization as of May 2026. An adverse Tax Court decision would likely trigger covenant violations in the company's $350 million credit facility. Cannabis companies trading on U.S. exchanges face unique delisting risks. Nasdaq and NYSE require minimum bid prices of $1.00 per share. Nineteen cannabis companies have executed reverse stock splits since January 2024 to maintain compliance. Acreage Holdings executed a 1-for-10 reverse split in March 2025, reducing outstanding shares from 187 million to 18.7 million and increasing the share price from $0.43 to $4.30. The stock subsequently declined to $1.87, requiring a second reverse split in November 2025. Shareholder derivative suits allege that boards breached fiduciary duties by failing to pursue alternative strategies including voluntary delisting to over-the-counter markets, where no minimum price requirements exist. Plaintiffs argue that reverse splits destroy shareholder value through dilution and increased volatility. Defense attorneys counter that maintaining exchange listings provides liquidity and institutional investor access that justify the splits. DEA registration delays impose quantifiable costs on research institutions. Johns Hopkins estimated that its 26-month application delay has cost $8.4 million in committed research funding that expired unused, $3.2 million in infrastructure costs for laboratories sitting idle, and $12 million in lost grant opportunities from NIH and private foundations. The institution calculated that each additional month of delay costs $890,000 in direct expenses and opportunity costs. The research bottleneck creates a circular policy trap. FDA requires substantial evidence of safety and efficacy from adequate and well-controlled studies to approve new drug applications. DEA registration is required to conduct such studies. But DEA considers lack of FDA-approved medical uses as a factor supporting continued Schedule I status. This cycle has persisted for 54 years since the CSA's enactment. Capital markets have responded to litigation uncertainty by demanding higher risk premiums for cannabis investments. Cannabis company bonds trade at spreads of 800-1,200 basis points over comparable treasuries, compared to 300-500 basis points for similarly rated companies in other industries. Equity valuations reflect 40-60% discounts to comparable retail and pharmaceutical companies based on EV/EBITDA multiples. Green Thumb Industries trades at 8.2x forward EBITDA compared to 18.4x for comparable specialty retail chains.

What Experts Say

Tax attorneys, policy analysts, and industry economists agree that litigation has become a substitute for legislative reform, with unpredictable results. Rachael Yeager, partner at Vicente Sederberg LLP and former Colorado Assistant Attorney General, said the Tax Court has become "an accidental cannabis policy forum" where judges make industry-wide determinations without the institutional competence or democratic legitimacy of Congress. According to Yeager, the court's case-by-case approach creates inconsistent outcomes that fail to provide clear guidance to operators or IRS examiners. Andrew Kline, partner at Perkins Coie and former deputy director of the Office of National Drug Control Policy, described the DEA registration backlog as "administrative paralysis driven by political risk aversion." Kline noted that DEA career staff understand the research applications have merit but lack political cover to approve them while marijuana remains Schedule I. According to Kline, the agency has created de facto policy through inaction. Kris Krane, president of 4Front Ventures and board member of the National Cannabis Industry Association, characterized reverse stock split litigation as "a symptom of the broader federal-state conflict." Krane explained that cannabis companies face corporate governance challenges unknown to other industries because federal prohibition prevents access to traditional banking, institutional investment, and exchange listings that other sectors take for granted. Beau Whitney, senior economist at Whitney Economics, calculated that 280E costs the cannabis industry $3.1 billion annually in excess federal taxes compared to normal tax treatment. Whitney projected that rescheduling to Schedule III would increase industry-wide EBITDA by 34% and enable $8.2 billion in additional capital investment over five years. According to Whitney, the economic stakes in the DEA administrative proceeding exceed those in any previous cannabis litigation. Hilary Bricken, partner at Harris Bricken and chair of the firm's cannabis practice group, said IRS enforcement has become "increasingly aggressive and sophisticated" as the agency develops institutional expertise in cannabis taxation. Bricken noted that early IRS examinations often accepted questionable cost allocation methodologies, but current audits employ forensic accounting techniques and challenge every aspect of operators' tax positions. According to Bricken, the days of favorable IRS settlements have ended. Sam Kamin, professor at University of Denver Sturm College of Law and co-director of the school's Constitutional Rights and Remedies Program, described the litigation landscape as "a second-best solution to a first-order policy failure." Kamin argued that courts lack the tools to resolve fundamental tensions between federal prohibition and state legalization, and that judicial decisions inevitably create new problems while solving narrow technical questions.

What's Next

Three pending decisions will shape cannabis federal litigation for the next decade: the DEA rescheduling determination, the Tax Court's decision in Patients Mutual Assistance Collective Corp. v. Commissioner, and the Second Circuit's ruling in Feinberg v. Curaleaf Holdings. The DEA administrative law judge hearing on marijuana rescheduling is scheduled to conclude in September 2026, with an initial decision expected by December 2026. DEA Administrator review would follow, with a final rule possible by mid-2027. If DEA reschedules marijuana to Schedule III, Section 280E would no longer apply, eliminating the basis for $4.2 billion in pending tax disputes. Operators would file amended returns claiming refunds for prior years still within the statute of limitations. The IRS would face a potential $12 billion refund liability for taxes paid under 280E since 2019. However, rescheduling faces substantial opposition. The National Association of Drug Court Professionals, Smart Approaches to Marijuana, and several county sheriffs' associations have intervened in the proceeding to oppose Schedule III placement. These parties argue that marijuana's abuse potential and lack of FDA-approved formulations support continued Schedule I status. If DEA maintains Schedule I status, the litigation wave will continue with operators exhausting administrative appeals before seeking judicial review in federal courts of appeals. The Tax Court's decision in Patients Mutual Assistance Collective Corp. v. Commissioner, expected in August 2026, will address whether a cannabis dispensary's delivery service constitutes a separate trade or business eligible for deductions. The case involves $23 million in disputed deductions for delivery driver wages, vehicle expenses, and logistics software. A taxpayer victory would create a roadmap for operators to bifurcate activities and reduce 280E impact. An IRS victory would foreclose this planning strategy and increase effective tax rates industry-wide. The Second Circuit's decision in Feinberg v. Curaleaf Holdings, a shareholder derivative suit challenging the company's 1-for-4 reverse stock split, will establish precedent for director liability in cannabis corporate governance. Oral arguments are scheduled for July 2026, with a decision expected by November 2026. The case presents the question whether directors of federally prohibited businesses owe modified fiduciary duties that account for unique regulatory constraints. A plaintiff victory would expose cannabis company directors to personal liability for defensive corporate actions, potentially making it difficult to recruit qualified board members. A defense victory would insulate directors from second-guessing of decisions made to navigate federal-state conflicts. Congress remains deadlocked on cannabis reform legislation. The SAFE Banking Act has passed the House seven times since 2019 but has never received a Senate floor vote. The Cannabis Administration and Opportunity Act, which would deschedule marijuana entirely, has 23 Senate cosponsors but lacks the 60 votes needed to overcome a filibuster. The MORE Act, which would remove marijuana from the CSA and expunge prior convictions, passed the House in 2020 and 2022 but died in the Senate both times. Without legislative action, federal litigation will continue to accumulate. The Tax Court's docket of cannabis cases is projected to reach 12,000 by the end of 2027 based on current IRS examination rates. DEA's registration application backlog will grow to over 150 pending matters by early 2027 if processing times do not improve. Securities litigation will expand as more cannabis companies face delisting and execute reverse splits. The Supreme Court has consistently denied certiorari in cannabis tax cases, suggesting the justices see the issue as appropriate for legislative rather than judicial resolution. The Court's denial of review in Standing Akimbo, Patients Mutual, and Olive left circuit splits unresolved and declined opportunities to clarify 280E's constitutional limits. This pattern suggests the Court will not intervene absent a direct circuit conflict on a dispositive legal question.

Further Reading

• Controlled Substances Act, 21 U.S.C. § 801 et seq. — https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13.pdf
• Internal Revenue Code Section 280E, 26 U.S.C. § 280E — https://www.govinfo.gov/content/pkg/USCODE-2021-title26/pdf/USCODE-2021-title26-subtitleA-chap1-subchapB-partIX-sec280E.pdf
• DEA Notice of Proposed Rulemaking on Marijuana Rescheduling (May 2024) — https://www.federalregister.gov/documents/2024/05/21/2024-10586/schedules-of-controlled-substances-rescheduling-of-marijuana
• U.S. Tax Court Cannabis Docket — https://www.ustaxcourt.gov/docket.html
• Californians Helping to Alleviate Medical Problems, Inc. v. Commissioner, 128 T.C. 173 (2007) — https://www.ustaxcourt.gov/UstcInOp/OpinionViewer.aspx?ID=5638
• Standing Akimbo, LLC v. United States, 955 F.3d 1146 (10th Cir. 2020) — https://www.ca10.uscourts.gov/opinions/19/19-1050.pdf
• Administrative Procedure Act, 5 U.S.C. § 551 et seq. — https://www.govinfo.gov/content/pkg/USCODE-2021-title5/pdf/USCODE-2021-title5-partI-chap5.pdf
• HHS Recommendation to Reschedule Marijuana (August 2023) — https://www.hhs.gov/about/news/2023/08/30/hhs-recommends-rescheduling-marijuana.html
• Securities Exchange Act of 1934, 15 U.S.C. § 78a et seq. — https://www.govinfo.gov/content/pkg/USCODE-2021-title15/pdf/USCODE-2021-title15-chap2B.pdf
• National Cannabis Industry Association Litigation Tracker — https://thecannabisindustry.org/litigation-tracker/